April 13, 2004Neurology
Practice Parameter: Recurrent stroke with patent foramen ovale and atrial septal aneurysm: RETIRED
Why the study?
Does warfarin reduce subsequent stroke or death compared to aspirin in patients with cryptogenic stroke and PFO or ASA?
Population
Patients with a cryptogenic stroke and a patent foramen ovale (PFO), atrial septal aneurysm (ASA), or both.
Comparison
Warfarin vs Aspirin
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Insufficient evidence favors warfarin over aspirin; leaves open optimal antithrombotic strategy in cryptogenic stroke with PFO.
Structured PICO
Does warfarin reduce subsequent stroke or death compared to aspirin in patients with cryptogenic stroke and PFO or ASA?
P
Population
Patients with a cryptogenic stroke and a patent foramen ovale (PFO), atrial septal aneurysm (ASA), or both.
I
Intervention
Warfarin
C
Comparator
Aspirin
O
Outcome
Subsequent stroke or deathhard clinical
In patients with cryptogenic stroke and PFO or ASA, there is insufficient evidence to determine if warfarin is superior to aspirin for preventing recurrent stroke or death, though warfarin increases minor bleeding.
Cite This Study
Messé et al. (2004) studied this question.